amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Company profile
Ticker
FOLD
Exchange
Website
CEO
John Crowley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMICUS THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
1.Callidus Biopharma, Inc. • 2.Celenex, Inc. • 3.Scioderm, Inc. • 4.MiaMed, Inc. • 5.Amicus Therapeutics International Holding Limited • 6.Amicus Therapeutics UK Limited • 7.Amicus Therapeutics UK Operations Limited • 8.Amicus Therapeutics SAS • 9.Amicus Therapeutics B.V. • 10.Amicus Therapeutics GmbH ...
IRS number
200422823
FOLD stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
28 Feb 24
8-K
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
28 Feb 24
8-K
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
8 Jan 24
8-K
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
5 Dec 23
S-3ASR
Automatic shelf registration
8 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
8 Nov 23
D
$30.00 mm in equity, sold $30.00 mm, 2 investors
16 Oct 23
8-K
Termination of a Material Definitive Agreement
5 Oct 23
8-K
Entry into a Material Definitive Agreement
2 Oct 23
Transcripts
FOLD
Earnings call transcript
2023 Q4
28 Feb 24
FOLD
Earnings call transcript
2023 Q3
8 Nov 23
FOLD
Earnings call transcript
2023 Q2
8 Aug 23
FOLD
Earnings call transcript
2023 Q1
10 May 23
FOLD
Earnings call transcript
2022 Q4
1 Mar 23
FOLD
Earnings call transcript
2022 Q3
7 Nov 22
FOLD
Earnings call transcript
2022 Q2
5 Aug 22
FOLD
Earnings call transcript
2022 Q1
9 May 22
FOLD
Earnings call transcript
2021 Q4
24 Feb 22
FOLD
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
4
Samantha Prout
16 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
Bradley L Campbell
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Bradley L Campbell
19 Mar 24
4/A
Bradley L Campbell
15 Mar 24
4/A
John F Crowley
15 Mar 24
4/A
David Michael Clark
15 Mar 24
4/A
Jeff Castelli
15 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 266.27 mm | 266.27 mm | 266.27 mm | 266.27 mm | 266.27 mm | 266.27 mm |
Cash burn (monthly) | (no burn) | 1.27 mm | 8.24 mm | 15.71 mm | 12.78 mm | 12.78 mm |
Cash used (since last report) | n/a | 8.68 mm | 56.19 mm | 107.19 mm | 87.21 mm | 87.17 mm |
Cash remaining | n/a | 257.59 mm | 210.09 mm | 159.08 mm | 179.06 mm | 179.10 mm |
Runway (months of cash) | n/a | 202.6 | 25.5 | 10.1 | 14.0 | 14.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 219 |
Opened positions | 31 |
Closed positions | 22 |
Increased positions | 93 |
Reduced positions | 63 |
13F shares | Current |
---|---|
Total value | 3.57 tn |
Total shares | 295.82 mm |
Total puts | 639.40 k |
Total calls | 1.02 mm |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Perceptive Advisors | 27.69 mm | $336.75 bn |
Avoro Capital Advisors | 27.40 mm | $333.18 bn |
Vanguard | 27.13 mm | $329.92 bn |
BLK Blackrock | 20.94 mm | $254.65 bn |
Redmile | 16.94 mm | $206.05 bn |
JHG Janus Henderson | 14.93 mm | $181.57 bn |
JPM JPMorgan Chase & Co. | 13.01 mm | $158.19 bn |
STT State Street | 11.37 mm | $138.29 bn |
MS Morgan Stanley | 10.75 mm | $130.70 bn |
Palo Alto Investors | 10.52 mm | $127.97 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Prout Samantha | Common Stock | Payment of exercise | Dispose F | No | No | 10.66 | 7,027 | 74.91 k | 73,926 |
1 Apr 24 | Bradley L Campbell | Common Stock | Sell | Dispose S | No | No | 11.6661 | 7,500 | 87.50 k | 886,654 |
1 Apr 24 | Bradley L Campbell | Common Stock | Option exercise | Acquire M | No | No | 8.61 | 7,500 | 64.57 k | 894,154 |
1 Apr 24 | Bradley L Campbell | Stock Options Common Stock | Option exercise | Dispose M | No | No | 8.61 | 7,500 | 64.57 k | 60,000 |
15 Mar 24 | Bradley L Campbell | Common Stock | Payment of exercise | Dispose F | No | No | 11.48 | 13,375 | 153.55 k | 886,654 |
7 Mar 24 | Sblendorio Glenn | Common Stock | Option exercise | Acquire M | No | No | 2.8 | 15,000 | 42.00 k | 83,596 |
7 Mar 24 | Sblendorio Glenn | Stock Options Common Stock | Option exercise | Dispose M | No | No | 2.8 | 15,000 | 42.00 k | 0 |
5 Mar 24 | Michael Raab | Common Stock | Option exercise | Acquire M | No | No | 2.8 | 15,000 | 42.00 k | 83,596 |
5 Mar 24 | Michael Raab | Stock Options Common Stock | Option exercise | Dispose M | No | No | 2.8 | 15,000 | 42.00 k | 0 |
Press releases
WuXi Biologics Reports Solid 2023 Annual Results
26 Mar 24
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
1 Mar 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
28 Feb 24
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
8 Feb 24
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
1 Feb 24